There are a number of multimodality imaging methods that can aid an accurate diagnosis of HCM without the need for an invasive myocardial biopsy. It is important for clinicians to be aware of these and their limitations. Data from cardiac imaging can also guide risk stratification and it is important for clinicians to know how this can complement current practice.
- Multimodality imaging for SCD risk stratification in HCM
- Multimodality imaging to detect HCM phenocopies
- Role of echocardiography and multimodality imaging to guide interventions in HCM
- Panel: Putting multi-modality imaging into the clinical context
Speakers: Christopher M. Kramer, MD; Dr. Iacopo Olivotto; Steve R. Ommen, MD; Dr. Lynette Teo;
Moderators: Dr. Upasana Tayal
The Society for Cardiovascular Magnetic Resonance (SCMR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The Society for Cardiovascular Magnetic Resonance (SCMR) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Claiming CME
- Attend the sessions in full for which credit is sought
- Complete the post-activity evaluation
- A certificate of completion will be available once the evaluation is submitted
The planners and faculty for this activity did not have any relationships to disclose unless listed below. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.
Dr. Kramer receives research grants and consulting fees from Bristol Myers Squibb and Cytokinetics.
Dr. Teo receives speaker honararium from Siemens Healthineers; and is an advisory board member for AstraZeneca Singapore T-DXd ILD/Pneumonitis and AstraZeneca ADAURA.
Disclosure of Commercial
Support SCMR received funding to support this activity from the following organizations: None